Adult-onset temporal lobe epilepsy suspicious for autoimmune pathogenesis: Autoantibody prevalence and clinical correlates

Temporal lobe adult-onset seizures (TAOS) related to autoimmunity represent an increasingly recognized disease syndrome within the spectrum of epilepsies. In this context, certain autoantibodies (autoABs) were often associated with limbic encephalitis (LE). Here, we aimed to gain insights into (a) the distribution of ‘neurological’ autoABs (neuroABs, defined as autoABs targeting neuronal surface structures or ‘onconeuronal’ ABs or anti-glutamate acid decarboxylase 65 (GAD65) autoABs) in a large consecutive TAOS patient cohort, to characterize (b) clinical profiles of seropositive versus seronegative individuals and to find (c) potential evidence for other autoABs. Blood sera/cerebrospinal fluid (CSF) of TAOS patients (n = 800) and healthy donors (n = 27) were analyzed for neuroABs and screened for other autoABs by indirect immunofluorescence on hippocampal/cerebellar sections and immunoblots of whole brain and synaptosome lysates. Serological results were correlated with clinico-neuropsychological features. 13% of TAOS patients (n = 105) were neuroAB+, with anti-GAD65 and anti-N-methyl-D-aspartate receptors (NMDAR) as most frequent autoABs in this group. In our screening tests 25% of neuroAB- patients (n = 199) were positive (screening+), whereas all control samples were negative (n = 27). Intriguingly, key clinico-neuropsychological characteristics including magnetic resonance imaging (MRI) findings, epileptiform electroencephalographic (EEG) activity, and inflammatory cellular infiltrates in CSF were shared to a greater extent by neuroAB+ with neuroAB-/screening+ patients than with neuroAB-/screening- patients. Serological testing in a large consecutive TAOS patient series revealed seropositivity for anti-GAD65 autoABs as the most frequent neuroAB. Intriguingly, neuroAB+ individuals were virtually indistinguishable from neuroAB-/screening+ patients in several major clinical features. In contrast, neuroAB-/screening- TAOS patients differed in many parameters. These data support the potential presence of so far unrecognized autoABs in patients with TAOS.

[1]  G. Zanette,et al.  Epileptic seizures of suspected autoimmune origin: a multicentre retrospective study , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  J. Britton,et al.  Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune‐associated epilepsy: Conceptual definitions , 2020, Epilepsia.

[3]  C. Elger,et al.  Drebrin Autoantibodies in Patients with Seizures and Suspected Encephalitis , 2020, Annals of neurology.

[4]  J. Dalmau,et al.  Syndrome and outcome of antibody‐negative limbic encephalitis , 2018, European journal of neurology.

[5]  A. Koczulla,et al.  Ondine's curse and temporal lobe seizures: anti‐Hu‐ and Zic4‐associated paraneoplastic brainstem and limbic encephalitis , 2018, European journal of neurology.

[6]  R. Rouhl,et al.  Anti-GAD antibodies in a cohort of neuropsychiatric patients , 2018, Epilepsy & Behavior.

[7]  Maria Thom,et al.  Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery , 2017, The New England journal of medicine.

[8]  C. Kessler,et al.  Prevalence and outcome of late‐onset seizures due to autoimmune etiology: A prospective observational population‐based cohort study , 2017, Epilepsia.

[9]  J. H. Cross,et al.  Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology , 2017, Epilepsia.

[10]  K. Ding,et al.  Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology , 2017, JAMA neurology.

[11]  R. Köhling,et al.  Anti-GAD65 Containing Cerebrospinal Fluid Does not Alter GABAergic Transmission , 2016, Front. Cell. Neurosci..

[12]  A. Venkatesan,et al.  A clinical approach to diagnosis of autoimmune encephalitis , 2016, The Lancet Neurology.

[13]  N. Gilhus,et al.  Titin antibodies in “seronegative” myasthenia gravis — A new role for an old antigen , 2016, Journal of Neuroimmunology.

[14]  C. Elger,et al.  Serum from a Patient with GAD65 Antibody-Associated Limbic Encephalitis Did Not Alter GABAergic Neurotransmission in Cultured Hippocampal Networks , 2015, Front. Neurol..

[15]  C. Elger,et al.  A second chance—reoperation in patients with failed surgery for intractable epilepsy: long-term outcome, neuropsychology and complications , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  J. Dalmau,et al.  Autoimmune encephalopathies , 2015, Annals of the New York Academy of Sciences.

[17]  Tianxi Cai,et al.  Population-level evidence for an autoimmune etiology of epilepsy. , 2014, JAMA neurology.

[18]  C. Bien,et al.  Autoimmune epilepsies. , 2011, Current opinion in neurology.

[19]  R. Balice-Gordon,et al.  Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study , 2014, The Lancet Neurology.

[20]  V. Adam,et al.  Paraneoplastic limbic encephalitis in a patient with adenocarcinoma of the colon: a case report. , 2013, Journal of clinical anesthesia.

[21]  M. Brodie,et al.  Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy , 2013, Epilepsia.

[22]  B. Rudy,et al.  Encephalitis and antibodies to dipeptidyl‐peptidase–like protein‐6, a subunit of Kv4.2 potassium channels , 2013, Annals of neurology.

[23]  T. Braithwaite,et al.  Autoimmune Retinopathy , 2012, Ophthalmologica.

[24]  H. Urbach,et al.  Automated quantitative FLAIR analysis in hippocampal sclerosis , 2011, Epilepsy Research.

[25]  Christian G Bien,et al.  Autoantibodies associated with diseases of the CNS: new developments and future challenges , 2011, The Lancet Neurology.

[26]  P. Crino,et al.  Systemic and neurologic autoimmune disorders associated with seizures or epilepsy , 2011, Epilepsia.

[27]  I. Scheffer,et al.  Autoantibodies and epilepsy , 2011, Epilepsia.

[28]  J. Schott,et al.  Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis , 2011, Annals of neurology.

[29]  A. Vincent,et al.  NMDA Receptor Antibody Encephalitis , 2011, Current neurology and neuroscience reports.

[30]  M. Knip,et al.  Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy , 2010, Epilepsia.

[31]  H. Urbach,et al.  Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis , 2010, Annals of neurology.

[32]  D. Friedman,et al.  Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen , 2010, The Lancet Neurology.

[33]  C. Elger,et al.  Causes, presentation and outcome of lesional adult onset mediotemporal lobe epilepsy , 2009, Journal of Neurology Neurosurgery & Psychiatry.

[34]  Xiaoyu Peng,et al.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies , 2008, The Lancet Neurology.

[35]  L. Ramió-Torrentá,et al.  Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. , 2008, Brain : a journal of neurology.

[36]  C. Elger,et al.  Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy , 2007, Neurology.

[37]  H. Urbach,et al.  Serial MRI of limbic encephalitis , 2006, Neuroradiology.

[38]  H. Lassmann,et al.  Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. , 2004, Brain : a journal of neurology.

[39]  J. Honnorat,et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[40]  M. Rossor,et al.  Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. , 2004, Brain : a journal of neurology.

[41]  J. Honnorat,et al.  Oligoclonal T-cells in blood and target tissues of patients with anti-Hu syndrome , 2002, Journal of Neuroimmunology.

[42]  M. Rosenfeld,et al.  Molecular and clinical diversity in paraneoplastic immunity to Ma proteins , 2001, Annals of neurology.

[43]  A. Schulze-Bonhage,et al.  Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy , 2000, Neurology.

[44]  S. Gultekin,et al.  Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. , 2000, Brain : a journal of neurology.

[45]  J. Dalmau,et al.  Cell‐mediated autoimmunity in paraneoplastic neurological syndromes with anti‐Hu antibodies , 1999, Annals of neurology.

[46]  Loise M. Francisco,et al.  Tumor-specific killer cells in paraneoplastic cerebellar degeneration , 1998, Nature Medicine.

[47]  M. Rosenfeld,et al.  DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  M. Rosenfeld,et al.  T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis , 1998, Neurology.

[49]  L. Wilkins.  Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice , 1995 .

[50]  S. Tsuji,et al.  Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss , 1995, Clinical Neurology and Neurosurgery.

[51]  C. Bien,et al.  Neuropathology of autoimmune encephalitides. , 2016, Handbook of clinical neurology.